Immatics Nv Share Price (NASDAQ: IMTX)

$5.1

▲

-0.18

(-3.41%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Immatics Nv Stock chart to analyse performance

Immatics Nv stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$5.05
Today's High:$5.27
$5.10
0.98%
Downside
Day's Volatility :4.17%
Upside
3.23%
52 Weeks Low:$3.30
52 Weeks High:$13.09
$5.10
35.29%
Downside
52 Weeks Volatility :74.79%
Upside
61.04%

Immatics Nv Stock Returns

Period	Immatics Nv	Sector (Health Care)	Index (Russel 2000)
3 Months	-15.22%	3.6%	0.0%
6 Months	21.89%	-7.7%	0.0%
1 Year	-53.89%	-12.6%	0.0%
3 Years	-58.31%	10.2%	-4.1%

Immatics Nv Key Stats

Check Immatics Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$5.28
Open	$5.28
Today's High	$5.27
Today's Low	$5.05
Market Capitalization	$641.8M
Today's Volume	$2.6M
52 Week High	$13.09
52 Week Low	$3.3
Revenue TTM	$130.1M
EBITDA	$-78.3M
Earnings Per Share (EPS)	$-0.66
Profit Margin	-57.45%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-17.54%

Stock Returns calculator for Immatics Nv Stock including INR - Dollar returns

The Immatics Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Immatics Nv investment value today

Current value as on today

₹51,438

Returns

₹48,562

(-48.56%)

Returns from Immatics Nv Stock

₹53,846 (-53.85%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Immatics Nv Stock

-43%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Immatics Nv Stock from India on INDmoney has decreased by -43% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Immatics Nv

Name
Holdings %
Name
Holdings %
T. Rowe Price Investment Management,Inc.
15.08%
Suvretta Capital Management, LLC
9.90%
Baker Bros Advisors LP
8.37%
Perceptive Advisors LLC
7.72%
Vestal Point Capital LP
5.92%
RTW INVESTMENTS, LLC
5.73%

Analyst Recommendation on Immatics Nv Stock

Rating

Trend

Buy

92%Buy

7%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Immatics Nv(by analysts ranked 0 to 5 stars)

Immatics Nv Share Price Target

What analysts predicted

Upside of 167.97%

Target:

$13.67

Current:

$5.10

Immatics Nv share price target is $13.67, a slight Upside of 167.97% compared to current price of $5.10 as per analysts' prediction.

Immatics Nv Stock Insights

Price Movement
In the last 7 days, IMTX stock has moved down by -10.5%
Decreasing Revenue
Revenue is down for the last 3 quarters, 56.25M → 4.73M (in $), with an average decrease of 70.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 44.86M → -70.34M (in $), with an average decrease of 132.7% per quarter
IMTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 124.0%
IMTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 176.1%
Price to Sales
ForIMTX every $1 of sales, investors are willing to pay $4.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Immatics Nv Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$20.5M	↑ 389.36%
Net Income	$-35.3M	↑ 0.94%
Net Profit Margin	-172.05%	↑ 662.01%

	FY20	Y/Y Change
Revenue	$38.0M	↑ 69.4%
Net Income	$-279.0M	↑ 622.56%
Net Profit Margin	-733.84%	↓ 561.79%

	FY21	Y/Y Change
Revenue	$39.3M	↑ 11.23%
Net Income	$-107.5M	↓ 58.55%
Net Profit Margin	-273.45%	↑ 460.39%

	FY22	Y/Y Change
Revenue	$182.9M	↑ 397.17%
Net Income	$39.7M	↓ 139.46%
Net Profit Margin	21.71%	↑ 295.16%

	FY23	Y/Y Change
Revenue	$58.9M	↓ 68.76%
Net Income	$-105.8M	↓ 358.55%
Net Profit Margin	-179.63%	↓ 201.34%

	FY24	Y/Y Change
Revenue	$163.0M	↑ 188.6%
Net Income	$15.9M	↓ 115.69%
Net Profit Margin	9.77%	↑ 189.4%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$33.1M	↑ 91.24%
Net Income	$-3.3M	↓ 88.25%
Net Profit Margin	-10.09%	↑ 154.15%

	Q2 FY24	Q/Q Change
Revenue	$20.2M	↓ 38.4%
Net Income	$-19.4M	↑ 486.66%
Net Profit Margin	-96.09%	↓ 86.0%

	Q3 FY24	Q/Q Change
Revenue	$56.1M	↑ 169.58%
Net Income	$-9.5M	↓ 52.45%
Net Profit Margin	-16.95%	↑ 79.14%

	Q4 FY24	Q/Q Change
Revenue	$58.9M	↑ 11.26%
Net Income	$46.9M	↓ 623.49%
Net Profit Margin	79.75%	↑ 96.7%

	Q1 FY25	Q/Q Change
Revenue	$20.1M	↓ 66.97%
Net Income	$-43.1M	↓ 188.84%
Net Profit Margin	-214.48%	↓ 294.23%

	Q2 FY25	Q/Q Change
Revenue	$4.7M	↓ 74.51%
Net Income	$-70.3M	↑ 76.51%
Net Profit Margin	-1.5K%	↓ 1270.59%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-24.0M	↓ 28.34%

	FY20	Y/Y Change
Profit	$-43.6M	↑ 65.57%

	FY21	Y/Y Change
Profit	$-59.7M	↑ 47.39%

	FY22	Y/Y Change
Profit	$69.9M	↓ 225.07%

	FY23	Y/Y Change
Profit	$-70.5M	↓ 197.9%

	FY24	Y/Y Change
Profit	$163.0M	↓ 340.98%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-1.8M	↓ 90.43%

	Q2 FY24	Q/Q Change
Profit	$20.1M	↓ 1223.55%

	Q3 FY24	Q/Q Change
Profit	$56.1M	↑ 170.95%

	Q4 FY24	Q/Q Change
Profit	$58.9M	↑ 11.26%

	Q1 FY25	Q/Q Change
Profit	$20.1M	↓ 66.97%

	Q2 FY25	Q/Q Change
Profit	$4.7M	↓ 74.51%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$78.9M	↑ 243.1%
Investing Cash Flow	$-5.6M	↓ 62.56%
Financing Cash Flow	$-2.1M	↓ 107.87%

	FY20	Y/Y Change
Operating Cash Flow	$-104.1M	↓ 220.63%
Investing Cash Flow	$-19.4M	↑ 215.26%
Financing Cash Flow	$252.9M	↓ 11264.5%

	FY21	Y/Y Change
Operating Cash Flow	$-92.5M	↓ 4.47%
Investing Cash Flow	$8.5M	↓ 146.98%
Financing Cash Flow	$-3.0M	↓ 101.26%

	FY22	Y/Y Change
Operating Cash Flow	$106.0M	↓ 222.43%
Investing Cash Flow	$-222.0M	↓ 2899.83%
Financing Cash Flow	$130.9M	↓ 4834.4%

	FY23	Y/Y Change
Operating Cash Flow	$19.9M	↓ 81.8%
Investing Cash Flow	$-34.2M	↓ 85.04%
Financing Cash Flow	$92.2M	↓ 31.68%

	FY24	Y/Y Change
Operating Cash Flow	$-165.3M	↓ 966.96%
Investing Cash Flow	$-159.4M	↑ 385.49%
Financing Cash Flow	$334.5M	↑ 278.25%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-35.6M	↓ 141.47%
Investing Cash Flow	$-264.4M	↓ 507.19%
Financing Cash Flow	$190.9M	↓ 18173.36%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-35.7M	↑ 1.29%
Investing Cash Flow	$75.1M	↓ 128.71%
Financing Cash Flow	$-609.0K	↓ 100.32%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-37.5M	↑ 1.53%
Investing Cash Flow	$74.4M	↓ 4.03%
Financing Cash Flow	$-836.1K	↑ 33.04%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-61.2M	↑ 73.37%
Investing Cash Flow	$-49.6M	↓ 170.74%
Financing Cash Flow	$153.1M	↓ 19536.65%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-37.0M	↓ 41.5%
Investing Cash Flow	$50.6M	↓ 198.74%
Financing Cash Flow	$-797.0K	↓ 100.5%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-39.1M	↑ 14.18%
Investing Cash Flow	$64.2M	↑ 37.26%
Financing Cash Flow	$-727.0K	↓ 1.36%

Immatics Nv Technicals Summary

Sell

Neutral

Buy

Immatics Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Immatics Nv Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Immatics Nv	-21.37%	21.89%	-53.89%	-58.31%	-44.56%
Regeneron Pharmaceuticals, Inc.	3.92%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-15.42%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	11.08%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Immatics Nv	29.31	NA	NA	-1.91	-0.18	-0.09	NA	3.82
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Immatics Nv	Buy	$641.8M	-44.56%	29.31	-57.45%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Immatics Nv

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Organization	Immatics Nv
Employees	554
CEO	Dr. Harpreet Singh Ph.D.
Industry	Health Technology

Key Management of Immatics Nv

Name	Title
Dr. Harpreet Singh Ph.D.	CEO, MD, Member of Management Board & Executive Director
Dr. Toni Weinschenk Ph.D.	Co-Founder & Chief Innovation Officer
Mr. Arnd Christ MBA	Chief Financial Officer
Mr. Steffen Walter Ph.D.	Chief Operations Officer
Mr. Edward A. Sturchio	General Counsel & Secretary
Dr. Carsten Reinhardt M.D., Ph.D.	Chief Development Officer
Dr. Rainer Kramer Ph.D.	Chief Business Officer & Site Head Munich
Mr. Cedrik M. Britten M.D.	Chief Medical Officer
Mr. Jordan Silverstein	Head of Strategy
Dr. Hans-Georg Rammensee Ph.D.	Co-Founder & Member of the Scientific Advisory Board

Important FAQs about investing in IMTX Stock from India :

What is Immatics Nv share price today?

Immatics Nv share price today is $5.10 as on August 30, 2025 at 1:29 am IST at the close of the market. Immatics Nv share today touched a day high of $5.27 and a low of $5.05.

What is the 52 week high and 52 week low for Immatics Nv share?

Immatics Nv share touched a 52 week high of $13.09 and a 52 week low of $3.30. Immatics Nv stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $5.10, lower by 61.04% versus the 52 week high.

How to invest in Immatics Nv Stock (IMTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Immatics Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immatics Nv Shares that will get you 0.2941 shares as per Immatics Nv share price of $5.10 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Immatics Nv Stock (IMTX) from India?

Indian investors can start investing in Immatics Nv (IMTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Immatics Nv stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Immatics Nv share’s latest price of $5.10 as on August 30, 2025 at 1:29 am IST, you will get 1.9608 shares of Immatics Nv. Learn more about fractional shares .

What are the returns that Immatics Nv has given to Indian investors in the last 5 years?

Immatics Nv stock has given -44.56% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?